CL2007003444A1 - Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. - Google Patents

Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.

Info

Publication number
CL2007003444A1
CL2007003444A1 CL200703444A CL2007003444A CL2007003444A1 CL 2007003444 A1 CL2007003444 A1 CL 2007003444A1 CL 200703444 A CL200703444 A CL 200703444A CL 2007003444 A CL2007003444 A CL 2007003444A CL 2007003444 A1 CL2007003444 A1 CL 2007003444A1
Authority
CL
Chile
Prior art keywords
pirrolo
piridine
treatment
pharmaceutical composition
inflammatory disease
Prior art date
Application number
CL200703444A
Other languages
English (en)
Spanish (es)
Inventor
Karen Price Stephen D Williams
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2007003444A1 publication Critical patent/CL2007003444A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200703444A 2006-11-30 2007-11-29 Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. CL2007003444A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US91762007P 2007-05-11 2007-05-11
US94474307P 2007-06-18 2007-06-18

Publications (1)

Publication Number Publication Date
CL2007003444A1 true CL2007003444A1 (es) 2008-06-27

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703444A CL2007003444A1 (es) 2006-11-30 2007-11-29 Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.

Country Status (14)

Country Link
US (1) US7855216B2 (enExample)
EP (1) EP2099796B1 (enExample)
JP (1) JP5211063B2 (enExample)
AR (1) AR064031A1 (enExample)
AT (1) ATE511509T1 (enExample)
AU (1) AU2007325123B2 (enExample)
CA (1) CA2672327A1 (enExample)
CL (1) CL2007003444A1 (enExample)
DK (1) DK2099796T3 (enExample)
PE (1) PE20081354A1 (enExample)
PL (1) PL2099796T3 (enExample)
PT (1) PT2099796E (enExample)
TW (1) TW200829586A (enExample)
WO (1) WO2008067481A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2729635A1 (en) * 2008-07-03 2010-01-07 Ananth Srinivasan Compounds and processes for production of radiopharmaceuticals
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
SG187633A1 (en) * 2010-07-30 2013-03-28 Oncotherapy Science Inc Quinoline derivatives and melk inhibitors containing the same
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
EP3624795B1 (en) 2017-05-19 2022-04-20 NFlection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
ES3030506T3 (en) 2017-05-19 2025-06-30 Nflection Therapeutics Inc Pyrrolopyridine-aniline compounds for treatment of dermal disorders
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
JP7546297B2 (ja) 2018-11-20 2024-09-06 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのチエニル－アニリン化合物
CA3120337A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
EP4436570A4 (en) 2021-11-23 2025-10-22 Nflection Therapeutics Inc FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS
AU2023213905A1 (en) * 2022-01-28 2024-07-11 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2023166450A1 (ko) * 2022-03-04 2023-09-07 삼진제약주식회사 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025100940A1 (ko) * 2023-11-07 2025-05-15 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1501797B1 (en) * 2002-04-23 2009-08-05 Aventis Pharmaceuticals Inc. 3-(substituted amino)-1h-indole-2-carboxylic acid ester and 3-(substituted amino)-benzo[b]thiophene-2-carboxylic acid ester derivatives as interleukin-4 gene expression inhibitors
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Also Published As

Publication number Publication date
ATE511509T1 (de) 2011-06-15
HK1135099A1 (en) 2010-05-28
AU2007325123B2 (en) 2012-12-13
PT2099796E (pt) 2011-09-06
CA2672327A1 (en) 2008-06-05
AU2007325123A1 (en) 2008-06-05
PL2099796T3 (pl) 2011-10-31
TW200829586A (en) 2008-07-16
DK2099796T3 (da) 2011-09-05
AR064031A1 (es) 2009-03-04
JP2010511626A (ja) 2010-04-15
US20080242655A1 (en) 2008-10-02
PE20081354A1 (es) 2008-11-14
WO2008067481A1 (en) 2008-06-05
EP2099796B1 (en) 2011-06-01
JP5211063B2 (ja) 2013-06-12
EP2099796A1 (en) 2009-09-16
US7855216B2 (en) 2010-12-21

Similar Documents

Publication Publication Date Title
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
EP1748765A4 (en) Pharmaceutical suspension composition
IL184901A0 (en) 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
IL185484A0 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
CL2008000751A1 (es) Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c.
EP2037917A4 (en) Pharmaceutical composition comprising amlodipine and losartan
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
CL2007003472A1 (es) Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
CL2007002376A1 (es) Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas.
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
ZA200706672B (en) 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
EP1862183A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING A WATER-SOLUBLE DEATH MEDICINE
BRPI0619911A2 (pt) composto, pró-droga, agente farmacêutico, e, uso do composto
ZA200710146B (en) New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
ZA200710404B (en) Pharmaceutical composition comprising 2, 3-dihydro-6-nitroimidazo [2, 1-b] oxazole derivatives
BRPI0611748A2 (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
PL1890695T3 (pl) Zastosowanie 2,5-dipodstawionych pochodnych tiazol-4-onu w lekach
IS8559A (is) Lyfjasamsetning gegn sveppagerlum